Addition of Aprepitant (Emend®) to Standard Antiemetic Regimen Continued for 7 Days after Chemotherapy for Stem Cell Transplantation Provides Significant Reduction of Vomiting

Oncology (Switzerland)

Volumn 89, Issue 1, 2015, Pages 31-36

  Svanberg, Anncarin ^a,b   Birgegård, Gunnar ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antiemetic; Aprepitant; Chemotherapy; Chemotherapy induced nausea vomiting; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BETAMETHASONE; LORAZEPAM; MELPHALAN; METOCLOPRAMIDE; PLACEBO; ANTIEMETIC AGENT; DEXAMETHASONE; MORPHOLINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HEALTH CARE QUALITY; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; MIDDLE AGED; MULTIPLE MYELOMA; NAUSEA; STEM CELL TRANSPLANTATION; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MORPHOLINES; MULTIPLE MYELOMA; NAUSEA; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VOMITING;

EID: 84937526513     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000371523     Document Type: Article

References (21)

1. Hesleth PI, Kris MG, Grundberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindlev CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103.
2. American Society of Clinical Oncology; Kris MG, Hesleth PI, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
3. Girish C, Manikandan S: Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Indian J Cancer 2007; 44: 25-30.
4. Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2006, pp 1000-1003.
5. Rittenberg CN: A new class of antiemetic agents on the horizon. Clin J Oncol Nurs 2002; 6: 103-104.
6. Poli-Bigeli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 12.
7. Hesketh PJ, Grunberg SM, Gralla RJ, et al; Aprepitant Protocol 052 Study Group: The oral neurokinin-1 antagonist receptor aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
8. Lees J, Marotti R: Nausea and vomiting in bone marrow transplant patients-an investigation of the incidence, timing and related factors. Support Care Cancer 2005; 13: 418-419, abstract 04-032.
9. Bubalo JS, Leis JF, Curtin PT, et al: A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: 9112.
10. Adel NG, Khan A, Lucarelli C: Use of palonosetron 0.25 mg IV daily and incidence of nausea and vomiting in patients undergoing bone marrow transplantation (BMT). Journal of Clinical Oncology (ASCO Annual Meeting Proceedings, Post-Meeting Edition) 2006, vol 24, No. 18S (June 20 Supplement): 16510.
11. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, Amadori D, Bella MA, Gramatzio V, Donati D, et al: Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9: 675-678.
12. Smith DB, Newlands ES, Rustin GJ, Begent RH, Howells N, McQuade B, Bagshawe KD: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487-490.
13. Verweij J, de Wit R, de Mulder PH: Optimal control of acute cisplatin-induced emesis. Oncology 1996; 53(suppl 1):56-64.
14. Hickok JT, Roscoe JA, Morrow GR, Bole CW, Zhao H, Hoelzer KL, et al: 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005; 6: 765-772.
15. Rolla F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: result of the Perugia consensus conference. Ann Oncol 2010; 21(suppl 5):232-243.
16. Paul B, Trovato JA, Thompson J, Badros AZ, Goloubeva O: Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 2010; 16: 45.
17. Pielichowski W, Barzal J, Gawronski K, Mlot B, Oborska S, Wasko-Grabowska A, Rzepecki P: A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011; 43: 3107-3110.
18. Stiff PJ, Fox-Geiman MP, Kiley K, Rychlik K, Parthasarathy M, Fletcher-Gonzalez D, Porter N, Go A, Smith SE, Rodriguez TE: Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogeneic preparative regimens. Biol Blood Marrow Transplant 2013; 19: 49-55.
19. Bellm LA, Epstein J.B, Rose-Ped A, Martin R, Fuchs HJ: Patient reports of complications of bone marrow transplantation. Support Cancer Care 2000; 8: 33-39.
20. MacDonald P: Supportive care; in Scheinemann K, Boyce AE (eds): Emergencies in Pediatric Oncology. New York, Springer, 2012, chapt 14, pp 121-141.
21. Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK: How do patients expectancies, quality of life, and postchemotherapy nausea interrelate Cancer 2008; 113: 654-661.